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Abstract
Background: Treatment options for infections with soil-transmitted helminths (STH) - Ascaris lumbricoides, Trichuris
trichiura and the two hookworm species, Ancylostoma duodenale and Necator americanus - are limited despite their
considerable global health burden. The aim of the present study was to test the activity of an openly available FDA
library against laboratory models of human intestinal nematode infections.
Methods: All 1,600 drugs were first screened against Ancylostoma ceylanicum third-stage larvae (L3). Active compounds
were scrutinized and toxic compounds, drugs indicated solely for topical use, and already well-studied anthelmintics
were excluded. The remaining hit compounds were tested in parallel against Trichuris muris first-stage larvae (L1),
Heligmosomoides polygyrus third-stage larvae (L3), and adult stages of the three species in vitro. In vivo studies were
performed in the H. polygyrus and T. muris mice models.
Results: Fifty-four of the 1,600 compounds tested revealed an activity of > 60 % against A. ceylanicum L3 (hit rate of
3.4 %), following incubation at 200 μM for 72 h. Twelve compounds progressed into further screens. Adult A. ceylanicum
were the least affected (1/12 compounds active at 50 μM), while eight of the 12 test compounds revealed activity
against T. muris L1 (100 μM) and adults (50 μM), and H. polygyrus L3 (200 μM). Trichlorfon was the only compound
active against all stages of A. ceylanicum, H. polygyrus and T. muris. In addition, trichlorfon achieved high worm burden
reductions of 80.1 and 98.9 %, following a single oral dose of 200 mg/kg in the T. muris and H. polygyrus mouse model,
respectively.
Conclusion: Drug screening on the larval stages of intestinal parasitic nematodes is feasible using small libraries and
important given the empty drug discovery and development pipeline for STH infections. Differences and commonalities
in drug activities across the different STH species and stages were confirmed. Hits identified might serve as a starting
point for drug discovery for STH.
Keywords: FDA library, Soil-transmitted helminthiasis, Drug sensitivity assay, Trichuris muris, Ancylostoma ceylanicum,
Heligmosomoides polygyrus
Background
Infections with soil-transmitted helminths (STH) - Ascaris
lumbricoides, Trichuris trichiura and the two hookworm
species, Ancylostoma duodenale and Necator americanus -
are enormously prevalent and responsible for a main part
of the global health burden associated with neglected
tropical diseases. Approximately 1.45 billion people are
infected globally with at least one STH species [1]. In
2013, 4.0 million disability adjusted life years (DALYs)
were attributed to intestinal nematode infections [2].
Symptoms include malnutrition, iron deficiency, anemia,
intestinal obstruction, chronic dysentery, rectal prolapse,
and poor weight gain [3]. To date, the most cost-effective
public health strategy is to control morbidity by periodic-
ally administering anthelmintic drugs of mainly albenda-
zole and mebendazole, on a large-scale. In 2014, 138.2 and
258 million preschool-aged and school-aged children,
respectively, were treated with the benzimidazoles in
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endemic countries [4]. This number will increase consid-
erably over the next years, since more than 800 million
children require annual treatment with anthelmintic drugs
[4]. Drug resistance is a serious concern in light of the
enormous drug pressure. In addition, the spectrum of ac-
tivity of the benzimidazoles is sub-optimal; albendazole
and mebendazole have only low efficacy against the intes-
tinal nematode species T. trichiura when administered at
single doses [5]. It is therefore imperative that the drug
discovery pipeline produces viable alternatives.
Drug discovery for most of the STH is truly neglected.
For example, in 2014 as little as 678,299 and 171,197
USD were invested in drug discovery research for hook-
worm and T. trichiura infections, respectively (https://
gfinder.policycures.org/PublicSearchTool). To our know-
ledge there are no novel drug candidates for soil-transmitted
helminthiasis in the drug development pipeline.
In order to contribute to research and development
efforts for these neglected tropical diseases, a series of
libraries were screened for activity against hookworm
and/or whipworm in the framework of a Gates-funded
project in collaboration with the Drugs for Neglected
Disease initiative. Here we present our results with an
openly available FDA library. All 1,600 drugs were first
screened against the larval stages of A. ceylanicum. Ac-
tive compounds were examined and toxic compounds,
drugs indicated solely for topical use and already well-
studied anthelmintics were excluded. The remaining hit
compounds were tested in parallel against adult A. ceyla-
nicum and against T. muris L1 and Heligmosomoides
polygyrus L3 and adults in vitro. In vivo studies were
performed in the H. polygyrus and T. muris mice models.
Methods
Animals
Three-week-old male Syrian Golden hamsters were pur-
chased from Charles River (Sulzfeld, Germany). Four-
week-old female NMRI mice and female C57BL/10ScSn
OlaHsd mice (age 3 weeks) were purchased from Harlan
Laboratories (Horst, The Netherlands and Blackthorn,
United Kingdom, respectively). All animals were kept in
macrolon cages under environmentally-controlled condi-
tions (temperature: 25 °C, humidity: 70 %, light/dark cycle
12 h/12 h) and had free access to water (municipal tap
water supply) and rodent food. Rodents were allowed to
acclimatize for one week before infection. The current
study was approved by the local veterinary agency, based
on Swiss cantonal and national regulations (permission
no. 2070).
Drugs
The FDA Pharmakon compound library was purchased
from MicroSource Discovery Systems, Inc. (USA). Com-
pounds (10 mM, dissolved in DMSO) were stored at
-80 °C until use. Levamisole and ivermectin, used for the
in vitro controls, were purchased from Fluka and Sigma-
Aldrich, respectively (Buchs, Switzerland), dissolved at
10 mM stock solutions in DMSO, and stored at -20 °C
until further use. For the in vivo studies, bitoscanate,
chlorcyclizine HCl, clemastine, dicyclomine HCl, drofe-
nine HCl, ethopropazine HCl, lansoprazole, metformin
HCl, morantel, natamycin, trichlorfon, and trimipramine
maleate were purchased from Sigma-Aldrich.
In vitro tests on A. ceylanicum L3
A. ceylanicum larvae (L3) were obtained by filtering the
feces of infected hamsters and cultivating the eggs for 9 days
in the dark at 24 °C. L3 were washed in penicillin and
streptomycin-supplemented tap water and kept under re-
frigeration until used. For the drug assay, 40 L3 were placed
in each well of a 96-well plate for each compound, in dupli-
cate. Worms were incubated with 200 μM of the test drug
and culture medium, which was composed of 100 μl HBSS
medium (Hanks’ Balanced Salt Solution Modified; GIBCO,
Lucerne, Switzerland) supplemented with 25 μg/ml ampho-
tericin B, 100 U/ml penicillin, and 100 μg/ml streptomycin
(Sigma-Aldrich). Worms incubated with culture medium
and 1 % DMSO served as negative controls. Wells contain-
ing larvae, medium, and 200 μM of levamisole served as
positive controls. The plates were kept at room temperature
and in the dark for up to 72 h, after which the drug effect
was evaluated. To do so, first the total number of L3 per
well was determined. Then, 100 μl of hot water (≈80 °C)
was added to each well and the larvae that responded to
this stimulus (the moving L3) were counted. The propor-
tion of larval death was determined. A cut-off of 60 % was
used to define activity, hence compounds achieving > 60 %
larval death progressed to further testing.
In vitro tests on A. ceylanicum adult worms
Hamsters were infected per os with 150 A. ceylanicum L3.
Three weeks post-infection, hamsters were euthanized
with CO2 and the worms were collected from the intes-
tine. For each compound, three A. ceylanicum adults were
placed in each well of a 24-well plate, using 2 wells per
compound. Worms were incubated in the presence of
50 μM of the drug to be tested, and culture medium,
which was composed of HBSS medium supplemented
with 10 % Fetal Calf Serum (FCS) (Connectorate AG,
Dietikon, Switzerland), 25 μg/ml amphotericin B, 100 U/ml
penicillin, and 100 μg/ml streptomycin. Worms incubated
in 1 % DMSO in culture medium served as control. As a
positive control, ivermectin was used at a concentration of
50 μM. Worms were kept in an incubator at 37 °C and 5 %
CO2 for up to 72 h. Thereafter, the condition of the
worms was microscopically evaluated using a viability
scale from 3 (normal activity and no tegument alter-
ation) to 0 (dead, completely granulated).
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In vitro tests on T. muris L1 worms
Female C57BL/10ScSnOlaHsd mice were infected per os
with 200–250 T. muris eggs showing around 90–95 %
embryonation (checked microscopically). After 7 weeks,
T. muris eggs were collected from the feces of the
infected mice by the flotation method using saturated
NaCl solution in Milli-Q water. T. muris eggs were
stored in Milli-Q water in the dark for 3 months at 23–
25 °C, until the eggs were embryonated. The hatching
process to obtain T. muris L1 has been described else-
where [6]. For the assay, 40 L1 larvae were placed in
each well of a 96-well plate. Worms were incubated in
the presence of 100 μl RPMI 1640 medium with 12.5 μg/ml
amphotericin B, 500 U/ml penicillin, 500 μg/ml strepto-
mycin, and 100 μM of the drug to be tested. Each drug was
tested in duplicate. L1 larvae incubated with culture
medium and 1 % DMSO served as a negative control and
larvae incubated with levamisole at a concentration of
100 μM were included as a positive control. The assay was
kept in an incubator at 37 °C and 5 % CO2 for 24 h. At
24 h, the total number of L1 larvae per well was counted.
The larvae were then stimulated with 100 μl hot water
(≈80 °C) and the moving L1 larvae were counted.
In vitro assay with T. muris adult worms
Seven weeks post-infection of female C57BL/10ScSn
OlaHsd mice, T. muris adult worms were collected from
the intestines. Three T. muris adult worms were placed
in each well of a 24-well plate. Worms were incubated
with culture medium and 50 μM of the drug to be
tested. Each compound was tested in duplicate. Tri-
churis muris adult worms incubated with 1 % DMSO
and culture medium served as control. As positive con-
trol, levamisole was used at a concentration of 50 μM.
Worms were kept in an incubator at 37 °C and 5 % CO2
for 72 h and were subsequently microscopically evaluated
using a viability scale from 3 (normal activity and no tegu-
ment alteration) to 0 (dead, completely granulated).
Heligmosomoides polygyrus L3 in vitro studies
Female NMRI mice were infected with 80H. polygyrus
L3 per os. H. polygyrus eggs were obtained from infected
feces. The eggs were then placed on agar and, after
9 days in the dark at 24 °C, the L3 larvae hatched. For
the drug assay, 40 L3 larvae were placed in each well of
a 96-well plate. Worms were incubated in the presence
of 100 μl RPMI 1640 medium, supplemented with
0.63 μg/ml amphotericin B, 500 U/ml penicillin, 500 μg/ml
streptomycin, and 100 μM of the drug to be tested. Each
drug was tested in duplicate. Worms incubated with 1 %
DMSO and culture medium served as a negative control
and wells containing larvae, medium and 100 μM levami-
sole served as a positive control. The plates were kept at
room temperature for up to 72 h. To assess the effect of
the compound, the total number of L3 larvae per well was
counted, the larvae were stimulated with 100 μl hot water
(≈80 °C), and the moving L3 were counted.
In vitro assay with H. polygyrus adults
Female NMRI mice were infected with 80H. polygyrus
L3 per os. Two weeks post-infection, mice were dis-
sected and three adult worms were placed in each well
of a 24-well plate. Worms were incubated with culture
medium and 50 μM of the test drug. Each compound
was tested in duplicate. Adult worms incubated with
medium only and 50 μM levamisole and ivermectin
served as negative and positive control, respectively.
Worms were kept in an incubator at 37 °C and 5 % CO2
for 72 h and, subsequently, were microscopically evalu-
ated using a viability scale from 3 to 0.
Trichuris muris in vivo studies
C57BL/10ScSnOlaHsd mice were infected with 200 em-
bryonated T. muris eggs per os. The drinking water for
the mice contained dexamethasone (1 mg/ml) in order
to suppress their immune system to avoid rejection of
the infection. At 42 days post-infection, the stool was
collected and filtered to check for the presence of eggs.
Infected mice were placed in individual cages. The
compounds were administered by gavage at dosages of
10–400 mg/kg (guided by the LD50 values of the drugs).
The dose volume was adjusted according to the mouse’s
body weight, which was assessed for each mouse directly
prior to treatment. Four to six untreated mice served as
controls. After 72 h, the stool was collected from each
cage to check and count the dead worms released
through the stool. Six days post-treatment, animals were
killed by the CO2 method and the gastrointestinal tract
was collected. The intestine was dissected and adult
worms were collected and counted.
Heligmosomoides polygyrus in vivo studies
NMRI mice were infected with 80H. polygyrus L3 per os.
Fourteen days post-infection, mice were treated orally
with the test drugs at dosages of 10–400 mg/kg. Four to
six untreated mice served as controls. Ten days post-
treatment, animals were killed by the CO2 method, and
the gastrointestinal tract was collected. The intestine was
dissected and adult worms were collected and counted.
Statistics
For the in vitro drug sensitivity assays, all viability scores/
larval survival counts were averaged across replicates and
normalized to the average viability scores/larval survival
counts of the control wells (Microsoft Office Excel 2010)
using the following formula: Drug effect (%) = 100 % –
[100 % * (No. of live larvae alive/Total No. of larvae) drug/
(No. of live larvae/Total No. of larvae) control]. To
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calculate the drug effect in in vivo studies, the worm bur-
den (WB) of treated animals was calculated and compared
with the worm burden of control mice, which were in-
fected simultaneously but were not treated. The worm
burden reduction (WBR) was calculated as follows: WBR
(%) = 100 % – (100 % * WB treatment/WB control). The
worm expulsion rates were calculated as follows: (c/d) ×
100, where c is the total number of expelled worms in a
treated group and d is the total worm count (expelled
worms as well as worms present in the gut counted fol-
lowing dissection) of the same group. The Kruskal-Wallis
test (Statsdirect, statistical software version 2.8.0) was used
to determine statistical significance of WBRs at a level
of 0.05.
Results
In vitro studies
The study flow is presented in Fig. 1. From 1,600 com-
pounds tested, 54 compounds revealed an activity of
> 60 % against A. ceylanicum L3 (hit rate of 3.4 %),
following incubation at 200 μM for 72 h. Twenty of these
compounds killed all L3. Results are summarized in
Table 1. The activities of the standard drugs, levamisole
and ivermectin, (also included in the library) are pre-
sented as reference. Both drugs resulted in death of
all A. ceylanicum L3.
Of the 54 compounds, 12 compounds have a topical
indication and 19 drugs are toxic or are associated with
severe adverse events. Twelve drugs (including levami-
sole and ivermectin) are well-known anthelmintics and,
with exception of bitoscanate and morantel (for which
little information on the efficacy against these parasites
is available), were therefore not considered for further
testing in the framework of this work. One drug,
ftaxilide was not commercially available. Hence, 12
compounds progressed into further screens. Against adult
A. ceylanicum, only trichlorfon resulted in death of the
worms, while the remaining 11 compounds revealed low
activity (< 60 % activity). Eight of the 12 compounds
affected H. polygyrus L3, with an activity of > 75 %. Adult
H. polygyrus showed slightly higher sensitivity to the drugs
as compared to adult A. ceylanicum, with dicyclomine
HCl and ethopropazine HCl resulting in death of all
worms, and trichlorfon and morantel revealing an activity
of 79 and 80 %, respectively.
Against T. muris L1, nine of the 12 test compounds
showed an activity ranging from 78–100 %, at a concen-
tration of 100 μM after 24 h of incubation. Six of these
compounds caused death of all worms. The parallel tests
on adult T. muris yielded nine compounds with high ac-
tivity (75–100 %) against T. muris adults, of which five
compounds were lethal. There was a good correlation
between larval and adult activity: two compounds were
A. ceylanicum
L3
200 µM
1600 compounds
A. ceylanicum
adult
50 µM
12 compounds
T. muris
in vivo
11 compounds
1546
compounds 
inactive/
42
compounds 
excluded
T. muris
L1
100 µM
12 compounds
T. muris
adult
50 µM
12 compounds
H. polygyrus
L3
200 µM
12 compounds
H. polygyrus
adult
50 µM
12 compounds
H. polygyrus
in vivo
12 compounds
Fig. 1 Screening flow applied testing a library of 1600 FDA approved compounds against A. ceylanicum, T. muris and H. polygyrus
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Table 1 In vitro activity profile of 56 FDA compounds (including 2 reference compounds) against A. ceylanicum and T. muris adult
and larval stages
Compound Drug effect (%)
A. ceylanicum L3
200 μM (72 h)
H. polygyrus L3
200 μM (72 h)
T. muris L1
100 μM (24 h)
A. ceylanicum adult
50 μM (72 h)
H. polyygrus adult
50 μM (72 h)
T. muris adult
50 μM (72 h)
Levamisole 100 100 100 0 56 100
Ivermectin 100 93 0 100 41 0
Abamectin 100 ND, anthelmintic
Amitriptyline HCl 91 ND, toxic
Apomorphine HCl 72 ND, toxic
Bifonazole 67 ND, topical application
Bitoscanate 100 20 100 28 34 100
Carbachol 89 ND, topical application
Chlorambucil 95 ND, toxic
Chlorcyclizine HCl 78 77 78 23 30 31
Chlorhexidine dihydrochloride 61 ND, topical application
Chloroxylenol 100 ND, topical application
Chlorpromazine 100 ND, toxic
Chlorprothixene HCl 100 ND, toxic
Chlorpyrifos 97 ND, toxic
Cisplatin 87 ND, toxic
Clemastine fumarate 76 91 2 47 30 100
Clomiphene citrate 80 ND, toxic
Coumophos 100 ND, toxic
Cyproheptadine HCl 88 ND, toxic
Dexlansoprazole 88 35 1 47 17 55
Diatrizoic acid 81 ND, toxic
Dibenzothiophene 100 ND, topical application
Dicyclomine HCl 71 88 7 42 100 93
Dimpylate 100 ND, toxic
Doramectin 100 ND, anthelmintic
Doxepin HCl 64 ND, toxic
Drofenine HCl 62 87 100 44 20 100
Dyclonine HCl 100 ND, topical
Eprinomectin 100 ND, anthelmintic
Ethopropazine HCl 100 89 100 33 100 100
Fenbendazole 66 ND, anthelmintic
Fenthion 97 ND, toxic
Ftaxilide 73 ND, commercially not available
Hexachlorophene 100 ND, topical
Histamine dihydrochloride 62 ND, topical
Mebendazole 78 ND, anthelmintic
Metformin HCl 100 11 100 50 27 75
Metitepine mesylate 70 ND, toxic
Morantel citrate 60 100 100 47 80 94
Moxidectin 100 ND, anthelmintic
Natamycin 95 14 100 53 10 61
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active against adult T. muris, but not active against L1.
Conversely, one compound showed no activity against
adult T. muris despite being active against L1 (Table 1).
Trichlorfon was the only compound active against all
stages of A. ceylanicum, H. polygyrus and T. muris.
In vivo studies against H. polygyrus
Identified hits from in vitro studies (n = 12) were further
evaluated for in vivo proof of principle. To maximize
chances of success, compounds were evaluated at high
doses. Single administrations were favored to mimic
dosing regimens used in mass drug administration pro-
grams for treatment of STH infections with the current
standard of care.
Low activity was observed for chlorcyclizine HCl,
clemastine, dicyclomine HCl, drofenine HCl, ethopropa-
zine HCl, lansoprazole, metformin HCl and trimipra-
mine maleate, with WBRs below 41 %. In mice treated
with a single oral dose of 400 mg/kg natamycin, a WBR
of 59.7 % was observed. The highest activities were ob-
served with bitoscanate and trichlorfon. Both dosages of
bitoscanate (100 and 50 mg/kg) resulted in significant
WBRs of 100 and 98.8 %, respectively. A WBR (98.9 %)
was achieved with a single oral dose of 200 mg/kg
trichlorfon, curing three of four treated mice (Table 2).
At 100 mg/kg trichlorfon, the calculated WBR was still
significant (81.9 %).
In vivo studies against T. muris
Nine of the 11 compounds tested in vivo revealed a low
activity against T. muris (WER < 7 % and WBRs < 45 %).
Natamycin and morantel were not tolerated by the mice
and five out of six mice died within 24 h post-treatment.
Treatment of infected mice with bitoscanate achieved a
WBR of 42 %, however, one of the mice died two days
after treatment. The highest activity was observed with
trichlorfon administered at 200 mg/kg, which resulted in
a WBR of 80 % and a WER of 67 %. Halving the dose to
100 mg/kg resulted in a low WBR and WER (28.8 and
3.3 %, respectively) (Table 2).
Discussion
Drug repurposing is the key drug discovery strategy for
human helminth infections, since anthelmintic drug
discovery and development has languished [7]. Veterin-
ary anthelmintics have obviously been the most attract-
ive candidates for cross-over development for the
treatment of human STH infections, since the regulatory
standards for veterinary drugs are compatible with those
for human drugs and a track-record of their use in animals
exists [8]. Indeed, all of the few anthelmintics currently
used for humans stem from veterinary medicine. In the
present work, we applied a broader repurposing strategy,
by evaluating 1,600 compounds from the FDA library,
which contains approved drugs over a range of indications.
While a handful of studies employing target screening
approaches have been conducted to identify new pharma-
cophores for the treatment of human STH infections [9],
phenotypic screening of selected libraries on parasitic
nematodes is basically non-existent. However, whole-
organism screens have several advantages over target-
based screening, since they are not constrained to single
Table 1 In vitro activity profile of 56 FDA compounds (including 2 reference compounds) against A. ceylanicum and T. muris adult
and larval stages (Continued)
Compound Drug effect (%)
A. ceylanicum L3
200 μM (72 h)
H. polygyrus L3
200 μM (72 h)
T. muris L1
100 μM (24 h)
A. ceylanicum adult
50 μM (72 h)
H. polyygrus adult
50 μM (72 h)
T. muris adult
50 μM (72 h)
Phenothiazine 98 ND, toxic
Phenylmercuric acetate 100 ND, topical
Pramoxine HCl 100 ND, topical
Pyrantel pamoate 91 ND, anthelmintic
Selamectin 79 ND, anthelmintic, topical
Tetramizole HCl 100 ND, anthelmintic
Thiabendazole 93 ND, anthelmintic
Thonzonium bromide 98 ND, topical
Trichlorfon 100 89 100 100 79 100
Triclosan 98 ND, topical
Triflupromazine HCl 83 ND, toxic
Trimeprazine tartrate 64 ND, toxic
Trimipramine maleate 62 79 99 7 23 75
Zoxazolamine 98 ND, toxic
Abbreviation: ND Not done
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targets (which are not well characterized for helminths)
[10]. Indeed, phenotypic approaches are more successful
for small-molecule, first-in-class medicines than target
based approaches [11]. High throughput assays with Cae-
norhabditis elegans often serve as a substitute for hel-
minth phenotypic assays, because most assays for parasitic
nematodes are laborious and low throughput. However,
the correlation of activity against C. elegans to parasitic
nematodes is not universal, with for example albendazole
lacking activity against C. elegans [12].
We observed a hit rate of 3.4 % against A. ceylanicum
larvae, our primary screen, with hits ranging across a
large spectrum of indications. For comparison, a hit rate
of ~7.6 % was observed against S. mansoni schistoso-
mula using the same library and also encompassing a
wide range of compound indications [13]. As highlighted
already for the S. mansoni screen [13], it was disappoint-
ing that many of the hits were unsuitable for further
testing, notably due to documented toxicity or restric-
tion to topical use. In addition, we excluded the com-
mon anthelmintics (e.g. mebendazole, pyrantel). Selected
compounds were next tested against a panel of hel-
minths, namely A. ceylanicum adults, H. polygyrus larvae
and adults, as well as T. muris larvae and adults. A few
observations are offered for discussion. First, A. ceylani-
cum L3 were selected for the primary screen since, com-
pared to adult stages, their use offers many advantages,
mainly in terms of ethical considerations, numbers avail-
able, and ease of provision [14]. However, larval stages
may not always be equally as sensitive as the target para-
site stage, the adult worms. For example, the veterinary
anthelmintic, monepantel, lacks activity against A. ceylani-
cum L3, while it is active against the adult worm [15].
Hence, larval-based assays should be validated in terms of
how larval sensitivity compares to the sensitivity of adult
worms. Additional file 1: Table S1 summarizes the activity
of all 54 A. ceylanicum L3 active drugs (including topical
and toxic drugs) against adult A. ceylanicum, T. muris L1
and adult T. muris. In general, A. ceylanicum L3 were
more sensitive in our assay to the test compounds than
the adult stages. Increased sensitivities of larval forms over
adult worms have been reported earlier including for S.
mansoni schistosomula [16]. Though a high false positive
rate (larval activity does not always translate to adult activ-
ity) is not optimally cost-effective, the risk of losing inter-
esting compounds is minimal, and in any case, larval pre-
screens are still more cost-effective and more ethical than
conducting the entire screen on adult stage worms.
Table 2 In vivo studies against H. polygyrus and T. muris
Treatment Dose
(mg/kg)
T. muris H. polygyrus
No. of mice
cured/investigated
Average
worm
number
Worm
burden
reduction (%)
Worm
expulsion
rate (%)
No. of mice
cured/investigated
Average
worm
number
Worm
burden
reduction (%)
Control a – 0/6 170.95 – – – — —
Control b – 0/4 163.5 – – – — —
Control c – 0/4 197.3 – – – — —
Control 1 0/8 61.3 —
Control 2 0/8 21.1
Control 3 0/12 47.0
Bitoscanatea,3 100 0/3* 70.5 58.8 0.3 4/4 0 100
Bitoscanate2 50 ND – – – 3/4 0.25 98.8¶
Chlorcyclizine HClc,1 100 0/3 115.0 41.7 0/4 39.5 35.6
Clemastineb,1 100 0/3 130.7 20.1 2.5 0/4 84.8 0
Dicyclomine HClb,1 400 0/3 245.5 0 39.1 0/4 36.8 40.1
Drofenine HCla,1 400 0/3 267.6 0 3.1 0/4 54.0 12.0
Ethoproprazine HClb,1 200 0/3 368.0 0 6.7 0/4 45.5 25.8
Lansoprazole1 400 ND – – – 0/4 43.0 29.9
Metformin HCla,1 400 0/3 140.6 17.7 0.6 0/4 80.0 0
Morantelc,1 400 0/3** 367.0 0 0 0/2**
Natamycina,1 400 0/3*** – – – 2/4 24.8 59.7
Trichlorfonc,1 200 1/3 34.0 80.1¶ 67.6 3/4 0.5 98.9¶
Trichlorfona 100 0/3 121.0 28.8 3.3 2/4 8.5 81.9¶
Trimipramine maleatec,1 10 0/3 113.3 42.6 0.1 0/4 71.5 0
Each * indicates a mouse that died. Superscripts 1–3 and a-c refer to the respective control groups ¶P < 0.05
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However, for T. muris this trend could not be confirmed
(Additional file 1: Table S1). Adult T. muris were equally
or even more sensitive than T. muris L1. Second, to our
knowledge, we have for the first time compared the sensi-
tivities of a small series of test drugs on larval and
adult stages of the two hookworm species. The H.
polygyrus model is widely used to study intestinal
nematode infections, as it is easy to maintain in the
laboratory and far more cost-effective than other
laboratory hookworm rodent models [17]. The
activity of compounds on A. ceylanicum L3 and
H. polygyrus L3 was similar (only bitoscanate, dexlanso-
prazole, metformin and natamycin lacked activity against
H. polygyrus L3). Similarly, the A. ceylanicum adult
screen mirrored the adult H. polygyrus screen (ex-
cept for dicyclomine HCl and ethopropazine, which
showed activity against adult H. polygyrus). Hence,
our results with a small panel of compounds sup-
port the use of H. polygyrus in the framework of
anthelmintic drug discovery.
Only two compounds revealed activity in vivo, namely
trichlorfon and bitoscanate. In addition, a moderate ac-
tivity was observed with natamycin against H. polygyrus
(two out of four mice cured), while the drug was not tol-
erated by T. muris infected mice. The low in vivo activity
of many of the in vivo tested drugs might not be surpris-
ing, as bioavailable drugs from the FDA library of 1,600
approved drugs may not have the ideal profile for in vivo
activity. Though there are exceptions (e.g. levamisole,
ivermectin or albendazole) an ideal treatment for STH,
particularly Trichuris spp. infections should be only
poorly absorbed in order to target worms sitting in the
gastrointestinal tract.
In vivo, trichlorfon revealed high activity against
H. polygyrus and T. muris, while bitoscanate showed
high activity against hookworm but was moderately
active against T. muris. The organophosphate trichlorfon
is mainly used as an ectoparasiticide [18]. However, it is
also known for its antischistosomal properties [trichlor-
fon (metrifonate) was marketed for the treatment of
S. haematobium prior to the advent of praziquantel] [19]
and is applied for the control of intestinal nematode
parasites of cattle and sheep. Trichlorfon is particularly
used for nematodes that have developed resistance to
other commonly-used anthelmintics [20]. In the past
years, it was investigated for the treatment of Alzhei-
mer’s disease. Metrifonate, at various fixed and loading
doses, was associated with significant cognitive improve-
ment compared to placebo, where the slow-release
break-down byproduct, 2,2-dichlorovinyl dimethyl phos-
phate (DDVP), is supposed to be the active component
[21, 22]. The broad activity of metrifonate is perhaps not
surprising considering its mechanism of action; metrifo-
nate is a cholinergic drug, acting as an irreversible non-
selective acetylcholinesterase and butyrylcholinesterase
inhibitor [21]. There is a history of active cholinergic
anthelmintics including pyrantel and levamisole, which
are both selective nAChR agonists, and ivermectin
and moxidectin, which are modulators of glutamate-
gated ion channels and nAChRs [23]. Emerging cholinergic
anthelmintics, monepantel, tribendimidine and derquantel
[24–26] have different nAChR subtype selectivities.
Bitoscanate was widely used prior to the advent of the
benzimidazoles for the treatment of hookworm infec-
tions [27, 28]. Despite its history of use, the literature is
very scarce. Bitoscanate belongs to the broad isothio-
cyanate class of anthelmintic compounds, which occur
widely in nature, particularly in plants of the mustard
(Brassicacae) family [29]. In India, clinical trials with
thousands of hookworm-infected patients were con-
ducted, which revealed a high efficacy of the drug.
Conflicting results were observed with regard to
Trichuris spp.; while a good trichuricidal activity was
observed in some settings [30], the high efficacy was not
consistently seen [28]. Mild and transient adverse events
were reported in the large number of studies done with
bitoscanate [28]. However, in the US bitoscanate is listed
as an extremely hazardous substance (http://nj.gov/health/
eoh/rtkweb/documents/fs/2172.pdf) which, when released
in certain amounts in the environment, may be of immedi-
ate concern to the community. A related compound,
amoscanate, was found to be effective against hookworm
and schistosomes in humans, but was accompanied
with severe liver toxicity in laboratory animals at high
doses [31, 32]. However, another related compound,
nitroscanate, is widely employed in veterinary medi-
cine to treat roundworm, hookworm and tapeworms
[33]. Currently, the isothiocyanates are researched for
activity against intestinal bacteria and cancer [34, 35].
The same library was screened against S. mansoni
larval stage and adult worms [13] with a very different set
of hits. When compared, 15 (27.8 %) of the compounds
identified as hits in this screen were also hits against
S. mansoni newly-transformed schistosomula (NTS)
(abamectin, chlorprothixene hydrochloride, clomiphene
citrate, doramectin, eprinomectin, hexachlorophene, met-
formin hydrochloride, metitepine mesylate, moxidectin,
natamycin, phenylmercuric acetate, selamectin, thonzo-
nium bromide, trichlorfon and triflupromazine hydro-
chloride). The vast majority of these common hits were
either toxic or for topical use only. However, it is also
noted that the macrocyclic lactones, a group that acts on
glutamate-gated ion channels [36], in general appear to be
active against both S. mansoni and hookworm.
Conclusions
In conclusion, we tested the FDA library of 1,600 approved
drugs using a screening cascade with the larval stages of
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the parasitic nematode, A. ceylanicum, as a primary
model. Our work has demonstrated that drug screening
on the larval stages of intestinal parasitic nematodes is
feasible using small libraries and shows differences
and commonalities in drug activities across the differ-
ent STH species and stages. A moderate hit rate of
3.4 % was observed with the FDA library of approved
drugs, however many of the active drugs consisted of
toxic compounds, compounds for topical use, or an-
thelmintics. Trichlorfon and bitoscanate were the only
active compounds in in vivo studies; however both
drugs have clear limitations. Nonetheless, structurally
related pharmacophores might serve as a starting
point for drug discovery for STH infections.
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